BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Breast cancer is the most common form of cancer in the female population across the globe.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Emerging Concept in Podiatry and Orthotics Industries: Impression boxes contain fine and soft foam for positive cast in orthotic and podiatry industries.

Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round.

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced that members of its executive team will participate at the following investor conferences.

InnoCare Pharma announced that the company has received Investigational New Drug approval of clinical trial from the NMPA for its novel targeted protein degrader ICP-490 for the treatment of multiple myeloma and non-Hodgkin’s lymphoma.

Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu’s STING technology.

Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 -induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion’s management in three scientific conferences in July 2022.

Regulatory News: Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, communicates additional preliminary data from the AAVance Phase 2/3 gene therapy trial in MPS IIIA.

Fact.MR’s recent study published on the global diabetes management software market provides detailed insights into prominent aspects favoring growth between 2022 and 2032.